Global Pharmacovigilance Market

The Global Pharmacovigilance Market size was valued at USD 8.25 Billion in 2023 and the total Global Pharmacovigilance Market revenue is expected to grow at a CAGR of 12.3% from 2024 to 2030, reaching nearly USD 18.58 Billion.

Global Pharmacovigilance Market Overview

The Global Pharmacovigilance Market has experienced rapid growth in recent years driven by activities related to the detection of side effects of drugs, assessments, understanding, and prevention and drug-related problems. It is essential because it identifies previously unknown Adverse effects. Patient safety, growing regulatory requirements, and the growing pharmaceutical industry are factors driving growth in of pharmaceutical Market. Also, the growing need for drug safety monitoring and the increasing complexity of drug development are the key drivers of the global Pharmacovigilance Market. In 2023, IQVIA held the largest market share of Pharmacovigilance followed by Parexel and ICON Plc. The introduction of novel therapeutics and rising demand for Pharmacovigilance systems to detect, assess, and prevent adverse drug reactions. Global regulatory bodies like the US FDA, the European Medicines Agency (EMA), and other regulatory bodies enforce strict regulations that are essential for global pharmaceutical companies to establish Pharmacovigilance protocols, therefore the market growing significantly. Additionally, the need for Pharmacovigilance has increased due to the rising prevalence of chronic diseases and medicine usage. Mediation errors and adverse drug reactions have serious side effects on patient’s health that cause high medical expenses. North America is dominating the global Pharmacovigilance Market with contract outsourcing Pharmacovigilance which is witnessing significant growth in the global market.

To know about the Research Methodology :- Request Free Sample Report

Global Pharmacovigilance Market Dynamics

Drivers: Rising Number of Adverse Drug Reactions (ADRs)

The global pharmacovigilance market is driven by the rising increasing adverse drug reactions (ADRs) on a global scale. As the application of pharmaceutical products continues to expand, the unexpected adverse effects of drugs are rising. Pharmacovigilance plays an important role in the surveillance and reporting of ADRs, facilitating early identification, risk evaluation, and appropriate measures to safeguard patient well-being which are key drivers of the Global Pharmacovigilance market. The demand for pharmacovigilance services and software is fueled by the growing rate of adverse drug reactions. This drives the growth of the global pharmacovigilance market. The number of clinical trials has been increasing over the years as the pharmaceutical industries are developing new and better treatments for various diseases. This has led to an increase in the number of patients being exposed to new drugs, which has in turn led to an increase in the need for pharmacovigilance. The prevalence of chronic and serious diseases is also a key driver of the global Pharmacovigilance market. As the population ages, the number of people suffering from chronic diseases such as cancer and heart disease is increasing. This is leading to a greater need for Pharmacovigilance, as these patients are often taking multiple medications that need to be closely monitored for safety.

Lack of Awareness and Infrastructure in Developing Regions.

The lack of awareness in the global Pharmacovigilance market and developing countries. These regions face difficulties in establishing and implementing strong Pharmacovigilance systems. The Limited awareness regarding the significance of Pharmacovigilance, lacking regulatory frameworks, and resource restraints on the adoption of effective pharmaceutical practices, as poor infrastructure, a scarcity of skilled personnel, and inadequate data management systems affect the growth of the Pharmacovigilance Market in these regions.

Global Pharmacovigilance Market Segment Analysis

The global Pharmacovigilance Market is segmented based on type, application, end-user, clinical trial phases, and region. Pharmacovigilance is classified into two market types: contract outsourcing and in-house. The market is divided into segments based on applications like risk management, signal detection and evaluation, benefit-risk assessment, post-marketing surveillance, intensive monitoring programs, spontaneous reporting, and safety databases. By End-user it can be segmented into Pharmaceutical Companies, Contract Research Organizations (CROs), and Other Healthcare Providers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Analysis by Service Provider

In-house Pharmacovigilance most common and dominant type of Pharmacovigilance in the world market. Pharmacovigilance departments are established by pharmaceutical businesses, mainly major multinational companies, to secure control systems and observe to regulatory standards. In-house Pharmacovigilance improves their capacity to react quickly to new safety concerns by giving businesses direct authority and management over their safety data, However, contract outsourcing Pharmacovigilance is witnessing extensive growth and is considered the fastest-growing type in the global Pharmacovigilance Market. Benefits of the outsourcing strategy include cost-effectiveness, availability of specialist resources, and the chance to take benefit of CROs' vast Pharmacovigilance knowledge. Pharmaceutical businesses can also carefully manage their resources and concentrate on their core capabilities with help of outsourcing. Solutions like process design Standard Operating Procedures (SOP), Pharmacovigilance audits, and other specialized services are offered by contract outsourcing companies. Benefits of outsourcing Pharmacovigilance services include meeting aggressive pricing strategies, providing services relevant to extremely complicated regulatory requirements, and assisting in adding product lines to support expanding product portfolios. Additionally, contract outsourcing facilitates the efficient use of internal resources, expedites trial approval, and lessens the complexity of clinical studies.

Based on Clinical trials, The Pharmacovigilance Market is segmented into Preclinical I, Phase I, Phase II, Phase III, and Phase IV based on the stages of clinical trials. In 2023, phase IV which is the post-marketing sector held the largest market share, leading the global pharmacovigilance market. For the medications during clinical trials, these solutions serve as an extra safety precaution. Clinical studies must proceed to phase IV to detect any unexpected adverse drug reactions. Because this stage involves extensive drug testing on a wide patient base, the data gathered and evaluated is therefore expected to be of the most relevance following the medicine's commercialization.

The Phase III segment is expected to witness rapid growth during the forecast period. Phase III trials are conducted to determine and establish the efficacy of drugs. These trials also provide additional information regarding possible drug interactions, drug safety, and effectiveness before the commercialization of the drug. These factors are expected to increase revenue generation in the segment over the forecast period.

Analysis by Applications

In Pharmacovigilance, post-marketing surveillance is the most common type. It involves the systematic observation and assessment of pharmaceutical products' safety and effectiveness after their approval and distribution to the bigger population. When a drug is used widely this application is essential for identifying and evaluating adverse drug reactions (ADRs) and other potential safety issues. Pharmaceutical businesses and regulatory bodies obtain up-to-date information on medication safety through post-marketing surveillance, which helps them to make well-informed decisions about labeling, warnings, and possible legal action.

However, within Pharmacovigilance, signal detection, and evaluation are the applications that are expanding the fastest. It involves recognizing and evaluating signals, which could know established dangers connected to pharmaceutical items or possible safety problems. To find possible signals from big amounts of data, signal detection, and evaluation use a variety of techniques like data mining, statistical analysis, and pattern recognition. The growing importance of proactive risk management, improved access to healthcare data, and developments in data analytics are all contributing to the increasing popularity of this application. Pharmacovigilance stakeholders can reduce risks and guarantee patient safety by promptly identifying and assessing signals.

Competitive Landscape:

Due to the growing focus on medication safety, strict regulatory requirements, and the rising number of adverse drug events increasing globally, the global Pharmacovigilance industry is very competitive. The industry is made up of a wide variety of players, such as technology solution providers, pharmaceutical companies, business process outsourcing (BPO) companies, and contract research organizations (CROs). The worldwide Pharmacovigilance Market is defined by strategic alliances, mergers, and acquisitions that shape its competitive landscape. Businesses aim to capitalize on technology breakthroughs, increase their global reach, and improve their Pharmacovigilance capabilities. Additionally, there is a growing tendency of pharmaceutical companies to outsource their Pharmacovigilance operations to specialist service providers, which frees them up to concentrate on their primary R&D duties.

In Example,

1. Permira Advisers LLP completed the £703.1 million acquisition of Ergomed plc in November 2023. Ergomed is a distinct business that specializes in contract research services (CRO) and Pharmacovigilance (PV), with a specialization in uncommon diseases and difficult oncology.

2. LifeSphere NavaX was announced in December 2023 by ArisGlobal, a well-known Life Sciences technology business best known for its LifeSphere® platform. This new product is a sophisticated cognitive computing engine made to accelerate the digitization of IT operations used in research and development.

Global Pharmacovigilance Market Regional Insights

North America is dominating in the global Pharmacovigilance Market. Also, contract outsourcing is rising in North America. This can be attributed to several factors, including the presence of a well-established healthcare infrastructure, strict regulatory frameworks, and a high level of awareness regarding drug safety. Countries like the United States and Canada have strong Pharmacovigilance systems and experienced service providers. Additionally, the region's emphasis on technological advancements, strong collaborations between industry stakeholders, and the presence of key pharmaceutical companies contribute to the dominance of North America in the global Pharmacovigilance Market.

While the Asia Pacific region is the fastest-growing market for Pharmacovigilance. The region's pharmaceutical industry has been witnessing significant growth due to factors such as a large patient population, rising healthcare expenditure, increasing focus on research and development, and expanding regulatory requirements. Countries like China and India have emerged as major contributors to the growth of the Pharmacovigilance Market in the Asia-Pacific region. These countries have a vast pool of clinical trial participants, growing investments in healthcare infrastructure, and increasing adoption of Pharmacovigilance practices

The report aims to provide industry stakeholders with a thorough study of the Global Pharmacovigilance Market. The research presents the industry's historical and present state together with projected market size and trends, analyzing complex data in an easy-to-read manner. The research includes PORTER and PESTEL analyses along with the possible effects of market microeconomic factors. The analysis of both internal and external elements that could have a good or negative impact on the firm will provide decision-makers with a clear picture of the industry's future. By understanding the market segments and projecting the size of the Global Pharmacovigilance Market, the reports also help in understanding the market's dynamics and structure.

Pharmacovigilance Market Scope: Inquire before buying

Pharmacovigilance Market, by Region

Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Key Players

1. Accenture
2. IQVIA Inc.
3. Cognizant
4. IBM
5. Capgemini
6. ICON plc
7. ITClinical
8. United BioSource LLC
9. BioClinica (Clario)
10. Ergomed Group
11. Quanticate
12. Parexel International Corporation

Frequently Asked Questions:
1. What is the growth rate of the Global Pharmacovigilance Market during the forecast period?
Ans - The Global Pharmacovigilance Market is estimated to grow at a CAGR of 12.3% during the forecast period 2023-2030.

2. What is the Expected growth of the Global Pharmacovigilance Market size from 2023 to 2030?
Ans- The Global Pharmacovigilance Market size is estimated at US$8.25 billion in 2023. It is projected to reach US$18.25 billion by 2030.

3. What are the leading market players in the Global Pharmacovigilance Market?
Ans- Accenture, IQVIA Inc. Cognizant, IBM, Capgemini, and ICON plc. are the leading players in the Global Pharmacovigilance Market.

4. What are the major trends that would shape the future Global Pharmacovigilance Market?
Ans- The global pharmacovigilance market is influenced by increasing drug consumption and development rates, as well as the trend of outsourcing pharmacovigilance services.

5. What are the driving factors and opportunities in the market?
Ans- The Pharmacovigilance market is currently experiencing significant growth due to rising drug consumption and development rates, higher incidence of adverse drug reactions and drug toxicity, and increasing trends in outsourcing pharmacovigilance services.